CAOV-3

【CAOV-3】CAOV-3细胞/CAOV-3细胞/CAOV-3人乳头状卵巢腺癌细胞Cell line name Caov-3

Synonyms CaOv-3; CaOV-3; CAOV-3; CAOV3; CaOV3; CaOv3; Caov3; CA-OV-3; CaOV3 (S)

Accession CVCL_0201

Secondary accession CVCL_0231

Resource Identification Initiative To cite this cell line use: Caov-3 (RRID:CVCL_0201)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Part of: OCCP ovarian cancer cell line panel.

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2010-069.

Population: Caucasian.

Doubling time: 78 hours (PubMed=4016745); 68 hours (PubMed=25984343); ~44 hours (PBCF); 65.81 hours (JWGray panel).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Chromatin accessibility by ATAC-seq.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Genome sequenced.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Secretome proteome analysis.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Misspelling: CACOV-3; Note=Occasionally.

Misspelling: CaCOV3; Note=Occasionally.

Misspelling: CAVO3; Note=Occasionally.

Derived from site: In situ; Ovary; UBERON=UBERON_0000992.

PubMed=10318951; DOI=10.1073/pnas.96.10.5722; PMCID=PMC21927

Lau K.-M., Mok S.C., Ho S.-M.

Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.

Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999)

 

PubMed=12080474; DOI=10.1038/sj.onc.1205542

Manzano R.G., Montuenga L.M., Dayton M., Dent P., Kinoshita I., Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J.B., Auersperg N., Birrer M.J.

CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.

Oncogene 21:4435-4447(2002)

 

PubMed=18560578; DOI=10.1371/journal.pone.0002425; PMCID=PMC2409963

Faca V.M., Ventura A.P., Fitzgibbon M.P., Pereira-Faca S.R., Pitteri S.J., Green A.E., Ireton R.C., Zhang Q., Wang H., O'Briant K.C., Drescher C.W., Schummer M., McIntosh M.W., Knudsen B.S., Hanash S.M.

Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.

PLoS ONE 3:E2425-E2425(2008)

 

PubMed=19926575; DOI=10.1309/AJCPTK87EMMIKPFS; PMCID=PMC3040237

DeRycke M.S., Andersen J.D., Harrington K.M., Pambuccian S.E., Kalloger S.E., Boylan K.L.M., Argenta P.A., Skubitz A.P.N.

S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.

Am. J. Clin. Pathol. 132:846-856(2009)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20204287; DOI=10.3892/or_00000728; PMCID=PMC2909445

Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H., Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.

Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.

Oncol. Rep. 23:1021-1026(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170; PMCID=PMC3274821

Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D., Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B., Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A., Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.

Genomic complexity and AKT dependence in serous ovarian cancer.

Cancer Discov. 2:56-67(2012)